Skip to Main content Skip to Navigation
Journal articles

Signaling lymphocytic activation molecules Slam and cancers: friends or foes?

Abstract : Signaling Lymphocytic Activation Molecules (SLAM) family receptors are initially described in immune cells. These receptors recruit both activating and inhibitory SH2 domain containing proteins through their Immunoreceptor Tyrosine based Switch Motifs (ITSMs). Accumulating evidence suggest that the members of this family are intimately involved in different physiological and pathophysiological events such as regulation of immune responses and entry pathways of certain viruses. Recently, other functions of SLAM, principally in the pathophysiology of neoplastic transformations have also been deciphered. These new findings may prompt SLAM to be considered as new tumor markers, diagnostic tools or potential therapeutic targets for controlling the tumor progression. In this review, we summarize the major observations describing the implications and features of SLAM in oncology and discuss the therapeutic potential attributed to these molecules.
Complete list of metadata
Contributor : Jagadeesh Bayry Connect in order to contact the contributor
Submitted on : Sunday, January 26, 2020 - 11:01:10 AM
Last modification on : Wednesday, September 28, 2022 - 4:20:11 PM
Long-term archiving on: : Monday, April 27, 2020 - 4:19:09 PM


Publisher files allowed on an open archive



Gregory Fouquet, Ingrid Marcq, Véronique Debuysscher, Jagadeesh Bayry, Amrathlal Rabbind Singh, et al.. Signaling lymphocytic activation molecules Slam and cancers: friends or foes?. Oncotarget, Impact journals, 2018, 9 (22), pp.16248-16262. ⟨10.18632/oncotarget.24575⟩. ⟨inserm-02455443⟩



Record views


Files downloads